Relebactam is a small novel non-β-lactam inhibitor molecule structurally related to avibactam . It is combined with imipenem-cilastatin to form a β-lactam-β-lactamase inhibitor combination.
Recarbrio (imipenem/cilastatin/relebactam) (Fig. 4) was approved by the US FDA for the treatment of adults with HABP/VABP in 2019.
河北唯特医药科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!